MET Exon 14 Mutation–Positive NSCLC: FAQ Part 1

In this episode, Luis Paz-Ares, MD, PhD; D. Ross Camidge, MD, PhD; and Karen L. Reckamp, MD, MS, address questions on MET exon 14 testing and selecting MET-targeted therapies for patients with advanced NSCLC with topics including:Incorporating MET exon 14 testing into standard of careComparison of RNA-based and DNA-based NGS platformsAvailability of RNA-based NGS testing around the worldUsing FISH to quantify MET copy gain/amplificationRegulatory and clinical differences between new, selective MET inhibitorsSafety profiles of type I vs type II MET inhibitorsCounseling patients on management of peripheral edema, a class effect with MET inhibitor therapyInsights on combining MET inhibition with immune checkpoint inhibition therapy or chemotherapySelecting second-line therapy for a patient with MET exon 14–altered NSCLC progressing on tepotinib or capmatinibPresenters:Luis Paz-Ares, MD, PhDMedical OncologyUniversity Hospital Doce de OctubreMadrid, SpainD. Ross Camidge, MD, PhDProfessor of Medicine/OncologyUniversity of Colorado Cancer CenterAurora, ColoradoKaren L. Reckamp, MD, MSProfessor of MedicineDirector, Division of Medical OncologyDepartment of MedicineCedars SinaiLos Angeles, CaliforniaContent based on an online CME program supported by an independent grant from the Healthcare business of Merck KGaA, Darmstadt, Germany.Link to full program, including associated downloadable slidesets:https://bit.ly/2ExadCf

There are no comments yet.

Please log in to write the first comment.